Lexaria Bioscience Corp. (LEXX)

Lexaria Bioscience Cash Flow Statement

Financials in millions USD. Fiscal year is September - August.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Feb 28, 2026	Aug 31, 2025	Aug 31, 2024	Aug 31, 2023	Aug 31, 2022	Aug 31, 2021
Net Income	-9.54	-11.91	-5.81	-6.71	-7.38	-4.19
Depreciation & Amortization	0.09	0.09	0.08	0.15	0.1	0.11
Stock-Based Compensation	0.74	0.86	0.49	0.17	1.95	1.28
Other Adjustments	0.32	0.32	0.17	0.37	0.8	-1.26
Change in Receivables	0.29	-0.21	-0.04	0.03	-0.14	0.19
Changes in Inventories	-	-	-	0.04	-0	0.1
Changes in Accounts Payable	-1.61	0.4	0.83	0.09	0.05	0.01
Changes in Unearned Revenue	0	-0	0	-	-	-0.04
Changes in Other Operating Activities	0.33	0.02	-0.69	-0.01	-0.26	-0.19
Operating Cash Flow	-9.37	-10.45	-4.96	-5.88	-4.88	-3.99
Capital Expenditures	-0.04	-0.02	-0.04	-0.03	-0.05	-
Sale of Property, Plant & Equipment	-	-	-	-	-	0.27
Purchases of Intangible Assets	-0.05	-0.08	-0.15	-0.14	-0.13	-0.08
Purchases of Investments	-0.14	-0.14	-	-	-	-
Investing Cash Flow	-0.24	-0.24	-0.19	-0.17	-0.18	0.19
Long-Term Debt Issued	-	-	-	-	-	-0.02
Net Long-Term Debt Issued (Repaid)	-	-	-	-	-	-0.02
Issuance of Common Stock	8.21	6.05	10.32	1.59	-	13.49
Net Common Stock Issued (Repurchased)	8.21	6.05	10.32	1.59	-	13.49
Other Financing Activities	-	-	-	-	-0.04	-0.04
Financing Cash Flow	8.42	6.05	10.32	1.59	-0.04	13.42
Effect of Exchange Rate Changes on Cash and Cash Equivalents	0.06	-0.05	-0.02	-	-	-
Net Cash Flow	-1.34	-4.7	5.15	-4.46	-5.1	9.62
Free Cash Flow	-9.42	-10.48	-5	-5.91	-4.93	-3.99
FCF Margin	-2558.49%	-1483.88%	-1077.38%	-2614.84%	-1929.75%	-552.02%
Free Cash Flow Per Share	-0.45	-0.58	-0.40	-0.89	-0.84	-0.91
Levered Free Cash Flow	-10.76	-11.43	-5.62	-6.44	-7.43	-4.06
Unlevered Free Cash Flow	-10.7	-11.41	-5.58	-6.31	-6.78	-5.7

Updated Apr 13, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q